Intrauterine Lidocaine Infusion for Essure Sterilization Procedures

Pain Clinical Trial

Official title:

Intrauterine Lidocaine Infusion for Pain Management During Outpatient Essure Transcervical Tubal Sterilization Procedures

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00613834
• Other study ID #: OHSU FAMPLAN 3343
• Status: Completed
• Phase: Phase 4
• Start date: May 2007
• Est. completion date: June 2008

Study information

• Verified date: December 2019
• Source: Oregon Health and Science University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the level of pain women experience with an Essure procedure and the effect that lidocaine might have on that pain. We will also assess the absorption of lidocaine in the uterus by measuring lidocaine levels in the blood.

Description:

We intend to conduct a randomized, blinded, and placebo- controlled clinical trial at Oregon Health and Science University and Planned Parenthood of the Columbia Willamette to determine if intrauterine lidocaine infusion will decrease the amount of pain subjects experience during and after Essure transcervical tubal sterilization.

We plan to enroll women who have selected Essure as their method of tubal sterilization who will be randomized to one of two groups on the days of their procedures. Subjects in Group 1, the treatment group, will receive a standard paracervical block with lidocaine intrauterine infusion and subjects in Group 2, the control group, will receive a standard paracervical block with saline intrauterine infusion. The subjects will be asked to rate their pain on a 100 mm Visual Analog Scale (VAS) at five points during the procedure and once thirty minutes following the procedure. Subjects will also be asked to rate their overall satisfaction with their care prior to leaving the recovery room.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 58
• Est. completion date: June 2008
• Est. primary completion date: June 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Female

• Age 18 or older

• Good general health, based on the opinion of the investigator

• Voluntarily requesting permanent sterilization

• Negative pregnancy test

• Agree to premedication with ibuprofen and ativan

• English speaking, or other language if an interpreter is available to be present at all points of the study procedure.

• Willing and able to sign an informed consent

• Willing to comply with the terms of the study

Exclusion Criteria:

• Significant physical or mental health condition, based on the opinion of the investigator.

• Positive pregnancy test

• Request for IV/IM sedation prior to the start of the procedure

• Refusal of ibuprofen, ativan, or paracervical block

• Allergy to any study medication including lidocaine, ibuprofen, ativan, sodium bicarbonate

• History of toxic reaction to local anesthetics

• Known hepatic disease or liver dysfunction. (Lidocaine is metabolized by the liver.)

• Weight less than 100 pounds. [Any patient weighing less than 100 pounds would receive more than the recommended dose for their weight (4.5 mg/kg or 2 mg/lb)].

• Current participation in another research study which would interfere with the conduct of this study.

Related Conditions & MeSH terms

• Pain

Intervention

Drug:
• Lidocaine
5 ml intrauterine infusion of 4% lidocaine using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
• Sterile Saline
5 ml intrauterine infusion of sterile saline using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes

Locations

Country	Name	City	State
United States	Oregon Health & Science University	Portland	Oregon
United States	Planned Parenthood of the Columbia Willamette	Portland	Oregon

Sponsors (1)

Lead Sponsor	Collaborator
Oregon Health and Science University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Patient-perceived Pain Between Baseline and Cannulization	Patients rated their pain following speculum insertion (used as baseline) and after insertion of a cannula into both fallopian tubes. Reported pain during cannulization of the right and left fallopian tubes were averaged to obtain the measurement of pain at cannulization. Pain was reported using a Visual Analog Scale (VAS, range 0-100), where a score of 0 indicates no pain and a score of 100 indicates the worst pain imaginable. Baseline pain levels were subtracted from average pain during cannulization: a negative change in VAS score between baseline and cannulization indicates less pain during cannulization and a positive change in VAS score indicates more pain during cannulization.	Immediately after speculum insertion and immediately after cannulization
Secondary	Patient Perceived Pain 30 Minutes Post-procedure	Patients rated their pain 30 minutes after speculum removal using a Visual Analog Scale (VAS, range 0-100), where a score of 0 indicates no pain and a score of 100 indicates the worst pain imaginable.	30 minutes post-procedure
Secondary	Patient Satisfaction With the Essure Tubal Sterilization Procedure	Patients reported their overall satisfaction with the Essure tubal sterilization procedure using a Visual Analog scale (VAS), range 0-100. A score of 0 indicates lowest possible satisfaction and a score of 100 indicates highest possible satisfaction.	30 minutes post-procedure

External Links

•   (Women's Health Research Unit website)